Retinal degeneration is a time-dependent process in which the scientific questions that matter most – when does functional loss begin, how rapidly does it progress, and at what stage does intervention remain effective – all require dense, repeated measurements in the same animal. Histological endpoints (photoreceptor nuclei counts, outer nuclear layer thickness measured by OCT) provide structural precision but cannot indicate whether the surviving photoreceptors and inner retinal neurons actually process and transmit visual information. Electroretinography (ERG) requires anaesthesia, corneal electrode placement, and skilled operator involvement, making the dense temporal sampling that early-phase disease characterisation demands both logistically impractical and welfare-costly when repeated across large cohorts.

The OptoDrum resolves this problem directly. Its automated threshold determination requires no specialised electrophysiology infrastructure, can be run by any trained laboratory member, and produces operator-independent, continuous-scale output (cycles per degree; contrast sensitivity threshold) that scales from individual animal profiling through cohort-level longitudinal studies. Benkner et al. (2013) established the foundational visual function profiles for the most widely used RP models – rd1 and rd10 mice – providing the reference dataset against which all therapeutic studies in these models are calibrated. Cha et al. (2022) extended this to a stage-dependent characterisation, mapping how OptoDrum-measured acuity and contrast sensitivity align with structural and molecular milestones of photoreceptor loss. Carido et al. (2014) established OptoDrum-based functional baselines for the sodium iodate AMD surrogate model. Hollingsworth et al. (2022) demonstrated that chronic systemic proinflammatory conditions significantly accelerate functional visual decline, underscoring the importance of controlling inflammatory co-variables in longitudinal studies.

For aging-associated retinal degeneration and AMD models, see also the Systemic Aging & CNS Decline application page. For age-related macular degeneration as a focused cluster, see https://stria.tech/application/age-related-macular-degeneration. For the cross-disease retinal degeneration cluster, see https://stria.tech/application/retinal-degeneration. (Some of these cluster pages may be coming soon.)

Most inherited retinal dystrophies affect rod and cone photoreceptors with differing kinetics. Retinitis pigmentosa classically begins with rod loss, producing night blindness before any daylight vision is affected, but the sequence and relative severity vary substantially by genotype. In models based on rod-specific gene mutations – including Pde6b, RPGR, and VPS35 in the retina – standard photopic optomotor testing under room-illumination conditions captures only the downstream or secondary phase of functional loss; the primary rod-specific phase is missed entirely unless scotopic testing is performed. Conversely, cone-dominant dystrophies such as achromatopsia preferentially impair photopic visual function while sparing scotopic thresholds until late stages, making a photopic-only endpoint sufficient – but the only way to confirm this is to measure both independently.

Standard scotopic ERG provides a rod-specific functional readout but requires anaesthesia, pupil dilation, and corneal electrodes, and is poorly suited to the repeated measurements that characterisation and therapeutic studies require. The ScotopicKit combined with the DarkAdapt box provides a non-invasive automated alternative: animals are dark-adapted for a defined period in the fully light-tight DarkAdapt enclosure, then tested in the OptoDrum at calibrated low- luminance levels. Photopic and scotopic acuity can be obtained in the same animal on the same day, generating a complete rod/cone functional profile with no cumulative welfare cost and no specialist electrophysiology infrastructure. Repeated across the disease course, this dual profile provides both a mechanistic dissection of which photoreceptor class is primarily affected and a sensitive combined efficacy endpoint for therapeutic interventions targeting either or both classes.

For detailed information on rod-mediated night vision and scotopic visual function as a standalone topic, see https://stria.tech/application/night-vision. For inherited retinal dystrophies as a focused cluster, see https://stria.tech/application/retinal-dystrophy. For gene therapy approaches targeting rod photoreceptors specifically, see the Maintaining & Restoring Vision application page. (Some of these cluster pages may be coming soon.)

Neuroinflammation is now understood not merely as a secondary response to retinal degeneration but as an active co-driver of disease progression. Activated microglia accumulate in the subretinal space and outer plexiform layer of degenerating retinas, releasing reactive oxygen species, pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6), and complement components that accelerate photoreceptor death beyond what the primary genetic insult alone produces. This secondary inflammatory wave can contribute a substantial fraction of total photoreceptor loss in RP and AMD models, making neuroinflammation-targeted therapies a rational complement to gene-replacement or gene-silencing approaches (Silverman and Wong, 2020, Prog. Retin. Eye Res.).

The key translational challenge is determining whether suppressing a specific inflammatory target produces a functionally meaningful benefit – not merely structural photoreceptor survival. OptoDrum-based functional testing addresses this directly: if targeting microglial activation, TNF-alpha, or BET bromodomain proteins preserves or rescues optomotor visual acuity, the functional relevance of that inflammatory pathway to visual circuit integrity is established. This functional confirmation distinguishes genuine neuroprotective benefit from photoreceptors that survive structurally but fail to contribute to visual processing.

Critically, microglia are not uniformly damaging. Karg et al. (2023) provided direct functional evidence that certain microglial states are neuroprotective in aging-associated retinal degeneration and AMD contexts, with microglial dysfunction worsening OptoDrum-measured visual outcomes. Indiscriminate microglial depletion strategies therefore risk removing the protective early-stage population alongside the neurotoxic late-stage phenotype – a distinction that OptoDrum’s integrated circuit-level functional output captures as net outcome across timepoints. For the broader neuroinflammation literature across disease areas, see the Neuroinflammation & Autoimmune CNS Disease application page (21 Striatech publications) and the neuroinflammation cluster page at https://stria.tech/application/neuroinflammation. For microglial contributions specifically, see https://stria.tech/application/glial-suppression. (Some of these cluster pages may be coming soon.)

Gene therapy and optogenetics have fundamentally changed the prospects for inherited retinal disease: voretigene neparvovec (Luxturna) is approved for RPE65 mutations, and multiple AAV gene replacement, gene silencing, and optogenetics programmes are in clinical or advanced preclinical development. For each new programme, structural evidence of gene expression, photoreceptor survival, or opsin delivery is necessary but insufficient to advance a therapy – it must also be demonstrated that rescued or restored photoreceptors produce functional improvement at the circuit level in a behavioural context. For optogenetics specifically, where surviving inner retinal neurons are converted into light sensors using light-gated ion channels, the OptoDrum’s optomotor reflex paradigm provides the direct behavioural test of whether restored light responsiveness is functionally meaningful at the level of a visually guided reflex.

AAV dose optimisation is one of the most practically important and least well-standardised challenges in retinal gene therapy. Functional dose-response relationships – how much transduction coverage is needed to produce a detectable functional improvement, and what additional transduction coverage produces additional functional gain – are not derivable from structural or biochemical endpoints alone. Lu et al. (2024) demonstrated that OptoDrum-measured optomotor responses scale with AAV dose over a physiologically relevant range, establishing a quantitative dose-efficacy curve that directly informs clinical dose selection. Hulliger et al. (2020) defined the detection floor for this endpoint in severely degenerated retinas, establishing that even in advanced blindness, restored optomotor responses are detectable above background noise after opsin delivery – critical calibration data for interpreting negative or marginal results in late-stage disease models.

For the gene therapy cluster across all disease areas, see https://stria.tech/application/gene-therapy. For optogenetics specifically, see https://stria.tech/application/optogenetics. (These cluster pages may be coming soon.)

Neuroprotective strategies in retinal degeneration aim to delay or prevent photoreceptor and RGC death by targeting the downstream cell-death cascades on which all inherited degenerations converge: apoptosis (caspase-3/9 pathway), necroptosis (RIP1/3-MLKL cascade), Wallerian axon self-destruction (Sarm1-NAD⁺ axis), oxidative stress, and excitotoxicity. Gene- editing strategies such as RNA-targeting CRISPR offer an additional route by selectively silencing dominant gain-of-function mutations or pathogenic downstream effectors. The shared challenge across all of these approaches is demonstrating that structural rescue – confirmed by OCT, histology, or RGC count – translates to preserved visual circuit function. This translation is not guaranteed: structurally surviving photoreceptors or RGCs that remain metabolically compromised, synaptically disconnected, or embedded in a reorganised matrix may contribute minimally to visual processing. OptoDrum provides the definitive functional confirmation, measuring whether the circuit as a whole produces a behavioural visual response. It is therefore not merely a complementary endpoint but a logically necessary one for any neuroprotection study that claims translational relevance.

For axon-specific degeneration mechanisms including the Sarm1 and Wallerian degeneration pathway, see https://stria.tech/application/axon-degeneration. For RGC death specifically across disease contexts, see https://stria.tech/application/retinal-ganglion-cell-death. For optic nerve damage, see https://stria.tech/application/optic-nerve-damage. For ischemia-reperfusion injury models used alongside retinal degeneration, see also the Trauma & Acute Injury application page. (Some of these cluster pages may be coming soon.)

Rare inherited retinal diseases present a distinct set of methodological challenges: patient populations are small, genetic heterogeneity is substantial, and the relevant mouse models are often incompletely characterised relative to the canonical rd1/rd10 or RCS paradigms. Researchers entering this space frequently face an initial model characterisation problem: what is the functional visual phenotype of this model, how rapidly does it progress, and are therapeutic effects likely to be detectable above background variability with standard functional endpoints? Functional characterisation with the OptoDrum – producing a quantitative visual acuity and contrast sensitivity timeline – is typically the most practical first step, establishing the time course of functional decline and the measurement windows for subsequent intervention studies.

Kuchtey et al. (2024) directly addressed this for rare inherited glaucoma models, demonstrating that OptoDrum-based functional profiling in combination with structural and IOP measurements enables evidence-based model selection. Bossardet et al. (2026) characterised the sGC-deficient mouse as a mechanistically distinct genetic model spanning retinal degeneration and glaucomatous optic nerve pathology, with OptoDrum providing the primary functional timeline. Insignares et al. (2025) characterised progressive axial elongation in a model spanning five pillar-level disease contexts simultaneously, illustrating OptoDrum’s value as a unifying functional endpoint across mechanistically diverse rare disease models. Groh et al. (2021) extended this rationale to rare inherited neurological diseases with combined CNS and retinal involvement, where OptoDrum provides the retinal circuit functional component alongside systemic disease assessments. For a comprehensive overview of rare inherited diseases with CNS and eye involvement, see the Rare & Inherited CNS and Eye Disorders application page, which covers 20 Striatech publications. For the rare-disease cluster, see https://stria.tech/application/rare-disease. For myopia-related features in axial elongation models, see the Myopia, Refractive Development & Eye Growth application page. (Some of these cluster pages may be coming soon.)